Who are Relugolix CT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Leuprolide (GnRH agonists), Eligard (TM), Long acting FSH and GnRH antagonist, COS with GnRH antagonists and HP-HMG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/relugolix-ct.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Relugolix CT — Competitive Intelligence Brief

Relugolix CT (Relugolix CT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH receptor antagonist. Area: Oncology.

phase 3 GnRH receptor antagonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Relugolix CT (Relugolix CT) — University of Michigan. Relugolix CT works by inhibiting the activity of gonadotropin-releasing hormone (GnRH) receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Relugolix CT TARGET	Relugolix CT	University of Michigan	phase 3	GnRH receptor antagonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Leuprolide (GnRH agonists)	Leuprolide (GnRH agonists)	University of Pisa	marketed	GnRH agonist	GnRH receptor (GNRHR)
Eligard (TM)	Eligard (TM)	Chesapeake Urology Research Associates	marketed	GnRH agonist	GnRH receptor
Long acting FSH and GnRH antagonist	Long acting FSH and GnRH antagonist	Bioroma	marketed	GnRH antagonist / FSH receptor agonist combination	GnRH receptor, FSH receptor
COS with GnRH antagonists and HP-HMG	COS with GnRH antagonists and HP-HMG	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Gonadotropin protocol / Assisted reproductive technology regimen	GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH receptor antagonist class)

Sumitomo Pharma Switzerland GmbH · 1 drug in this class
University of Michigan · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Relugolix CT — Competitive Intelligence Brief. https://druglandscape.com/ci/relugolix-ct. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab